Startups

Biotech solution providing NGS-based metagenomic tests to fully identify pathogens.

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Seedtable Score

Score icon 48

Locations

Company Size

  • 11 - 51

Last Stage Round

Insights

PathoQuest, based in Paris, specializes in next-generation sequencing (NGS) to fully identify pathogens for healthcare providers. Its metagenomic tests offer a significant advantage over traditional methods like culture tests and PCR, which often result in delayed or inaccurate pathogen identification. By providing more precise diagnostics, PathoQuest aims to reduce ineffective treatments and associated healthcare costs. This focus appeals to health tech companies seeking efficient, cutting-edge solutions. With backing from prominent investors, PathoQuest is well-positioned to make a broad impact in biotech, improving pathogen detection and patient outcomes.

Total Funding
$26.1M

Investors

Premium Member Intelligence

    Access details of the company management, and other intelligence on this company via Seedtable Intel